Pluri Inc. (NASDAQ:PLUR) Sees Significant Increase in Short Interest

Pluri Inc. (NASDAQ:PLUR) was the target of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 76,809 shares, an increase of 265.2% from the October 15th total of 21,034 shares. Based on an average daily volume of 97,344 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.1% of the shares of the stock are sold short.

Pluri Stock Performance

NASDAQ:PLUR traded up $0.00 during trading hours on Friday, reaching $1.09. The company’s stock had a trading volume of 9,048 shares, compared to its average volume of 21,912. The firm has a market capitalization of $13.80 million, a price-to-earnings ratio of -0.45 and a beta of 0.64. The firm has a 50-day simple moving average of $1.10 and a 200-day simple moving average of $2.29. Pluri has a 1 year low of $0.85 and a 1 year high of $4.29.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter. The firm had revenue of $0.76 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has an average rating of “Sell”.

Insider Buying and Selling

In related news, Director Alexandre Weinstein Manieu purchased 833,334 shares of the business’s stock in a transaction on Friday, October 23rd. The stock was acquired at an average price of $1.50 per share, with a total value of $1,250,001.00. Following the purchase, the director directly owned 2,083,334 shares in the company, valued at approximately $3,125,001. This represents a 66.67% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 43.16% of the stock is currently owned by corporate insiders.

Pluri Company Profile

Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.